WILMINGTON, Del. and ANN ARBOR, Mich., June 13, 2017 /PRNewswire/ -- Hygieia, a pioneer in the field of insulin titration and management, and iSage Rx, creators of the iSage app, the first FDA cleared insulin titration platform that supports all brands of basal insulin, today announced a new technology collaboration. Hygieia will integrate the iSage Rx provider- and patient-dosing platform with Hygieia's proven d-Nav Insulin Guidance Service, beginning with basal insulin and eventually including all types of insulin. The iSage Rx platform will be configured to support Hygieia's existing insulin-titration algorithms, as well as additional brands and types of insulin not currently supported by Hygieia.
The integrated technology will support the expansion of Hygieia's successful health economic evaluation in Michigan, including the ongoing creation of a network of specialty-care clinics to support insulin management for people with diabetes. Hygieia will use the iSage Rx platform in the clinics to configure and prescribe Hygieia's proprietary, patented insulin-titration algorithms.
"Unfortunately, most patients who use insulin do not achieve optimal glycemic control and become susceptible to complications. It's especially unfortunate because insulin works, but there are still major challenges from both a provider and patient perspective that prevent patients from achieving the correct dose of insulin and optimal glycemic control," said Richard Bergenstal, M.D., executive director of the International Diabetes Center at Park Nicollet. "Frequent insulin-dose titration has achieved successful outcomes in numerous clinical trials, but in the current healthcare system, this is easier said than done. Healthcare providers often lack the expertise, resources and time to manage it, while patients may feel nervous about insulin intensification."
Hygieia's patented d-Nav technology is designed to empower patients to self-titrate insulin. Leveraging this technology, Hygieia established the highly successful d-Nav insulin management service in Northern Ireland that has transformed the way the NHS manages insulin users. In October 2016, Hygieia made the d-Nav service available for the first time in the United States through a one-year demonstration project in Michigan.
"Hygieia was first to recognize that there must be a better way to use insulin, and we've demonstrated that our d-Nav approach works. We are excited to be bringing this concept to the U.S. through a network of specialty-care clinics designed to simplify the process by which healthcare providers manage insulin," said Eran Bashan, CEO and co-founder, Hygieia Inc. "Healthcare providers can refer their patients to us and we'll take on the burden of managing their patients' insulin therapy. The game-changing combination of Hygieia and iSage Rx technology will provide patients on insulin proven success, peace of mind, and best-in-class technology."
"We're thrilled to support Hygieia's rapidly expanding network of specialty-care clinics. This collaboration exemplifies our approach of enabling other companies and technologies to integrate and offer insulin titration solutions; we're committed to creating the best insulin titration engine for patients with diabetes," said Ryan Sysko, CEO and founder, iSage Rx. "Our goal is to further support Hygieia by incorporating the capability to titrate all types of insulin including premix, bolus, basal plus GLP1, and U500 by the end of the year."
Hygieia is a digital insulin enhancement company dedicated to making insulin therapy easier for everyone involved. The company is based in Ann Arbor, Mich. and has a wholly owned subsidiary in the UK. More information is available at www.hygieia.com
About iSage Rx
iSage Rx, launched the iSage App, the first FDA 510(k)-cleared, prescription-only mobile application for the automated titration of all brands of basal insulin including Lantus, Levemir, Toujeo, Tresiba and Basaglar earlier this year. iSage allows physicians to choose from multiple clinically-validated basal insulin algorithms and tailor the algorithms to the specific needs of their type 2 diabetes patients. iSage Rx is a wholly-owned subsidiary of Amalgam Rx. For more information, visit http://isageapp.com
About Amalgam Rx
Amalgam Rx creates custom, digital therapies that combine clinical and behavioral health and interventions to engage, support and improve patient self-management. Amalgam's goal is to use technology to accelerate the impact and scale of medicine to improve the lives of millions of people living with chronic disease in partnership with life sciences companies, providers and other healthcare industry stakeholders. For more information, visit http://amalgamrx.com/
BOCA Communications for Amalgam Rx
Forward Health Communications, Inc. for Hygieia